Arteriocyte Medical Systems Inc.
Arteriocyte Medical Systems, Inc. is a leading medical device company committed to developing and marketing novel medical products to improve surgical outcomes. Established in 2007 by Arteriocyte, Inc. and DW Healthcare Partners, Arteriocyte Medical Systems is devoted to providing innovative solutions to patients and medical professionals to address serious unmet medical needs particularly in cardiac, orthopedic and vascular surgeries.
Arteriocyte is a clinical stage research and development biotechnology company that is developing proprietary, non-embryonic stem cell-based therapies targeted for the treatment of ischemia in patients suffering from coronary artery disease, peripheral vascular disease, stroke, and renal ischemia. The Company was founded in January of 2004 based upon more than four years of NIH-sponsored research utilizing stem cells to stimulate angiogenesis (new vessel growth). Arteriocyte’s ultimate goal is to develop umbilical cord blood - a rich source of stem cells - as the basis for the company’s future cellular medicines.
The company is currently conducting a Phase I clinical trial in the US (under an FDA approved IND) for an adult, bone-marrow-derived stem cell therapy designed to generate new blood vessels in ischemic tissues in patients suffering Chronic Ischemia. The clinical study is underway at University Hospitals of Cleveland.